Mitesh

NHS Business Services Authority (NHSBSA) has confirmed that the following 8 Eucerin® products will be granted upward retrospective pricing adjustments because the manufacturer did not update their product NHS list prices on the NHS dictionary of medicines and devices (dm+d) when the new list price changes took effect at the end of 2025.  Following checks [...]

The post Retrospective pricing adjustments for Eucerin® products appeared first on Community Pharmacy England.

In response to a significant ongoing disruption to the supply of Lansoprazole 15mg orodispersible tablets and Lansoprazole 30mg orodispersible tablets, two Serious Shortage Protocols (SSPs) have been issued by the Department of Health and Social Care (DHSC). Effective today 09 September 2026,  SSP088 and SSP089 provides that where supplies are available, but the prescription is [...]

The post Two SSPs issued for Lansoprazole 15mg and 30mg orodispersible tablets appeared first on Community Pharmacy England.

Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined August 2026 reimbursement prices for the following products to reflect an increase in their NHS list prices. To avoid pharmacy owners dispensing these products at a loss, DHSC has agreed to grant [...]

The post Retrospective reimbursement prices for August 2026 appeared first on Community Pharmacy England.

MHRA Class 2 Medicines Recall: Fingolimod Zentiva 0.5 mg Capsules (Zentiva Pharma UK Limited) Drug alert number: EL(26)A/37 Date issued: 20 August 2026 Zentiva UK Pharma Limited are recalling one batch of Fingolimod Zentiva 0.5 mg Capsules (BN 4L01372H) as a precautionary measure due to a potential risk of contamination with metal particles. DMRC reference [...]

The post MHRA Class 2 Medicines Recall: Fingolimod Zentiva 0.5 mg Capsules (Zentiva Pharma UK Limited) appeared first on Community Pharmacy England.

Cases of iatrogenic botulism have been reported following the therapeutic or cosmetic use of botulinum toxin containing products where the toxin’s effect extends beyond the area of treatment. Botulism caused by botulinum toxin is rare but can be life threatening. Symptoms can take up to four weeks to develop and may typically include difficulty breathing [...]

The post MHRA Drug Safety Update: Botulinum toxin type A products appeared first on Community Pharmacy England.